Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 10,964 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director George A. Scangos sold 10,964 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total transaction of $107,556.84. Following the transaction, the director now directly owns 708,295 shares of the company's stock, valued at $6,948,373.95. The trade was a 1.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Vir Biotechnology Trading Down 2.3 %

VIR stock traded down $0.23 during trading on Friday, hitting $9.57. 712,701 shares of the stock traded hands, compared to its average volume of 1,185,198. Vir Biotechnology, Inc. has a one year low of $6.56 and a one year high of $14.45. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -2.44 and a beta of 0.64. The company has a 50 day simple moving average of $9.31 and a 200 day simple moving average of $8.48.

Institutional Investors Weigh In On Vir Biotechnology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp increased its position in Vir Biotechnology by 10.4% in the 3rd quarter. State Street Corp now owns 5,625,533 shares of the company's stock valued at $42,135,000 after acquiring an additional 530,645 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Vir Biotechnology by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 2,196,601 shares of the company's stock worth $16,127,000 after buying an additional 7,827 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Vir Biotechnology by 58.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company's stock worth $14,059,000 after buying an additional 703,360 shares during the period. Millennium Management LLC grew its position in shares of Vir Biotechnology by 55.3% during the 4th quarter. Millennium Management LLC now owns 1,715,083 shares of the company's stock worth $12,589,000 after buying an additional 610,367 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Vir Biotechnology by 10.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,252,655 shares of the company's stock worth $9,194,000 after buying an additional 118,379 shares during the period. Institutional investors and hedge funds own 65.32% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Leerink Partners raised their price objective on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an "outperform" rating in a report on Monday, January 13th. Morgan Stanley raised shares of Vir Biotechnology from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $10.00 to $20.00 in a report on Thursday, January 9th. Needham & Company LLC reaffirmed a "buy" rating and set a $19.00 price objective on shares of Vir Biotechnology in a report on Wednesday, November 20th. Barclays cut their price target on shares of Vir Biotechnology from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Monday, November 4th. Finally, HC Wainwright reissued a "buy" rating and set a $110.00 price target on shares of Vir Biotechnology in a report on Friday, January 31st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Vir Biotechnology currently has a consensus rating of "Moderate Buy" and an average price target of $34.83.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).